文献速递胸部CT

住院2019冠状病毒病(COVID-19)患者CT视觉严重度评分时间变化及预后价值的多中心研究

Multicenter Study of Temporal Changes and Prognostic Value of a CT Visual Severity Score in Hospitalized Patients With Coronavirus Disease (COVID-19).
PubMed 文献 · AJR Am J Roentgenol · 2020-09-09

这项回顾性多中心研究纳入中国三家医院的161例住院COVID-19患者,采用CT视觉严重度评分评估系列胸部CT,并用广义样条回归刻画评分随时间的变化模式。评分在非重症存活者、重症存活者和死亡患者中依次升高,约在症状出现后9天和12天达峰后逐渐下降。基于CT评分和临床变量构建的预后模型在另一家医院135例患者的外部验证中,预测院内并发症的C-index为0.92-0.95。

要点

  • 住院第一周CT视觉肺部严重度评分中位数:非重症存活者2.0、重症存活者4.0、死亡患者11.0。
  • 存活者CT评分约在症状出现后9-12天达峰,随后住院各周逐渐下降。
  • 预后模型中院内并发症与重度CT评分(OR 31.28)、中度CT评分(OR 5.86)独立相关。

核心结论

  • CT视觉严重度评分与COVID-19临床疾病严重度相关,并在住院期间呈现特征性演变。
  • 基于CT视觉严重度评分和临床变量的预后模型在预测院内并发症方面表现良好,外部验证C-index为0.92-0.95。

研究设计与样本

  • 回顾性研究,纳入中国三家医院的161例住院COVID-19患者,住院期间接受系列胸部CT检查。
  • 采用视觉严重度评分系统评估CT,并用广义样条回归模型刻画住院期间系列CT评分的时间模式。
  • 利用CT视觉严重度评分和临床变量构建预测院内并发症(包括院内死亡)的预后模型。
  • 外部验证由两名独立放射科医师在另一家医院135例患者队列中完成。

关键影像表现/征象

  • 住院第一周CT视觉肺部严重度评分中位数:非重症存活者2.0,重症存活者4.0,死亡患者11.0。
  • 存活者CT视觉严重度评分约在症状出现后9天(非重症)和12天(重症)达峰,随后住院各周逐渐下降。

诊断标准与关键数值

  • 预后模型中,院内并发症与重度CT评分(OR 31.28)、中度CT评分(OR 5.86)、年龄(每增加1岁OR 1.09)、淋巴细胞计数(每增加1×10^9/L OR 0.03)独立相关。
  • 外部验证队列中,两名阅片者预测院内并发症的C-index为0.92-0.95,准确率85.2%-86.7%,敏感度70.7%-75.6%,特异度91.4%-91.5%。

临床应用与阅片要点

  • 作者认为,使用CT视觉严重度评分的预后模型可能有助于识别不良结局风险最高的患者并指导早期干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Chest CT findings have the potential to guide treatment of hospitalized patients with coronavirus disease (COVID-19). OBJECTIVE. The purpose of this study was to assess a CT visual severity score in hospitalized patients with COVID-19, with attention to temporal changes in the score and the role of the score in a model for predicting in-hospital complications. METHODS. This retrospective study included 161 inpatients with COVID-19 from three hospitals in China who underwent serial chest CT scans during hospitalization. CT examinations were evaluated using a visual severity scoring system. The temporal pattern of the CT visual severity score across serial CT examinations during hospitalization was characterized using a generalized spline regression model. A prognostic model to predict major complications, including in-hospital mortality, was created using the CT visual severity score and clinical variables. External model validation was evaluated by two independent radiologists in a cohort of 135 patients from a different hospital. RESULTS. The cohort included 91 survivors with nonsevere disease, 55 survivors with severe disease, and 15 patients who died during hospitalization. Median CT visual lung severity score in the first week of hospitalization was 2.0 in survivors with non-severe disease, 4.0 in survivors with severe disease, and 11.0 in nonsurvivors. CT visual severity score peaked approximately 9 and 12 days after symptom onset in survivors with nonsevere and severe disease, respectively, and progressively decreased in subsequent hospitalization weeks in both groups. In the prognostic model, in-hospital complications were independently associated with a severe CT score (odds ratio [OR], 31.28), moderate CT score (OR, 5.86), age (OR, 1.09 per 1-year increase), and lymphocyte count (OR, 0.03 per 1 × 109/L increase). In the validation cohort, the two readers achieved C-index values of 0.92-0.95, accuracy of 85.2-86.7%, sensitivity of 70.7-75.6%, and specificity of 91.4-91.5% for predicting in-hospital complications. CONCLUSION. A CT visual severity score is associated with clinical disease severity and evolves in a characteristic fashion during hospitalization for COVID-19. A prognostic model based on the CT visual severity score and clinical variables shows strong performance in predicting in-hospital complications. CLINICAL IMPACT. The prognostic model using the CT visual severity score may help identify patients at highest risk of poor outcomes and guide early intervention.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Wang X, Hu X, Tan W, et al. Multicenter Study of Temporal Changes and Prognostic Value of a CT Visual Severity Score in Hospitalized Patients With Coronavirus Disease (COVID-19). AJR Am J Roentgenol. 2020. PMID: 32903056. doi:10.2214/AJR.20.24044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。